BIOMIND LABS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.11 USD | 0.00% |
|
0.00% | +10.00% |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 27.36M 2.28B |
|---|---|---|---|---|---|
| Net income 2021 | -4M -334M | Net income 2022 | -2M -167M | EV / Sales 2021 | - |
| Net cash position 2021 | 2.23 185.79 | Net cash position 2022 | 0.02 1.5 | EV / Sales 2022 | - |
| P/E ratio 2021 |
-17.8
x | P/E ratio 2022 |
-9.17
x | Employees | 5 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 60.21% |
More Fundamentals
* Assessed data
More news
More press releases
| 3 months | +10.00% | ||
| 6 months | -78.85% | ||
| Current year | +10.00% |
1 month
0.11
0.11
Current year
0.090.57
1 year
0.090.57
3 years
0.097.01
5 years
0.097.01
10 years
0.097.01
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Oscar Leon
DFI | Director of Finance/CFO | - | - |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ravi Sood
CHM | Chairman | 48 | - |
Fraser Buchan
BRD | Director/Board Member | 40 | - |
Oscar Leon
DFI | Director of Finance/CFO | - | - |
Biomind Labs Inc. is a Canada-based biotech research and development company. The Company is primarily engaged in biotech platform that integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production with special focus on scientific research, clinical trials and in jurisdictions that open a fast track in the molecule to market lifecycle. Through its acceleration platform, it is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (DMT), 5-MeO-DMT, and mescaline for treating a range of therapeutic indications. 5-MeO-DMT is a powerful psychedelic tryptamine. Under the 5-MeO-DMT Program, the Company is focused on two drug candidates: BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and BMND08: 5-MeO-DMT novel formulation indicated for Alzheimerâs disease. Mescaline is a psychedelic alkaloid of the phenethylamine class. DMT Program is a serotonergic psychedelic.
Calendar
14/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +10.00% | 8.22M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BMND.F Stock
